BridgeMD
CAR T-cell therapy long term follow-up
EU CTIS ID: 2023-508128-37-00
What this study is testing
Describe selected, delayed AEs that are suspected to be related to previous CAR T-cell therapy as outlined in current Health Authority guidelines
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients must have received CAR T-cell therapy within one of the following: • Novartis or Penn sponsored CAR T-cell treatment trials where CAR T-cell therapy was given as monotherapy or as combination therapy. • Novartis managed access programs (MAPs) outside of the commercial setting, i.e. where CAR T-cell therapy was intended to be given in the setting of a Novartis or Penn sponsored CAR T-cell treatment trial
- Patients must provide informed consent/assent prior to their entry into this study
You likely can't join if
- There are no specific exclusion criteria for this study.
The study team makes the final eligibility decision.
Where it's taking place
- Singapore
- China
- Saudi Arabia
- United Kingdom
- Korea, Republic of
- Taiwan
- Japan
- Hong Kong
- United States
- Switzerland
- Australia
- Israel
- Canada
- Brazil
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Singapore; China; Saudi Arabia; United Kingdom; Korea, Republic of; Taiwan and 8 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.